<DOC>
	<DOC>NCT00905684</DOC>
	<brief_summary>This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC. Patients will be followed up approximately 6 months after initial visit. Selection of Study Population: Women can be enrolled after decision for treatment with Yasmin or any other OC has been made. Physicians should consult the full prescribing information for the respective OC before enrolling patients and familiarize themselves with the safety information in the product package label.</brief_summary>
	<brief_title>Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (YasminÂ® or Any Other Oral Contraceptives (OC)</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women who have been found eligible for OC use and have newly been prescribed an OC in accordance with the terms of the respective marketing authorization Starter (firstever user of an OC) and switcher from another OC (incl. women with a history of OC use) The contraindications and warnings of the Summary of Product Characteristics must be followed.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Compliance</keyword>
	<keyword>Hormonal Contraception</keyword>
</DOC>